why choose us

First received: July 28, 2023

Clinical Trial: Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Malignant Pleural Effusion

Study Type: INTERVENTIONAL


Official Title: Phase I Study of the IL-6 Receptor Antagonist Tocilizumab Delivered Via Pleural and Peritoneal Catheters

Brief Summary: The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE).Patients will have a total of 4 doses, one dose administered each week.Each dose will be greater than the previous one.

Read more